DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Gimeracil is an investigational drug.
There have been 59 clinical trials for Gimeracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.
There are one hundred and fourteen US patents protecting this investigational drug and nine hundred and thirty-six international patents.
Recent Clinical Trials for Gimeracil
|SOX-based CRT for Esophageal Cancer.||Zhejiang Provincial People’s Hospital||Phase 1/Phase 2|
|S-1 for 9 Months Versus 1 Year for Gastric Cancer Staged II（SMAC）||Fudan University||Phase 2|
|Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis||Zhejiang Cancer Hospital||Phase 2|
Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Gimeracil||Start Trial||Metal-salen complex compound, local anesthetic and antineoplastic drug||IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP)||Start Trial|
|Gimeracil||Start Trial||Multimodal silica-based nanoparticles||Start Trial|
|Gimeracil||Start Trial||Device and method for drug evaluation and local treatment||Kibur Medical, Inc. (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Gimeracil||European Patent Office||2738158||2031-06-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|